Abstract
White CM. The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia. Journal of cardiovascular pharmacology and therapeutics. 2018; 23: 372. DOI: 10.1177/1074248418769040
In the original on line version of this article, under Introduction, sentence 4 should read: The only investigational PCSK9 inhibitor in advanced phase III clinical trials had its development abandoned in 2017.
Under Conclusions, the second sentence should read.
Bococizumab’s phase III clinical trial program was halted after it was clear that the development of antibococizumab antibodies attenuates long-term LDL suppression and greater injection site reactions.
The correct reference 5 is given here.
Pfizer press release. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. November, 2017. Available at: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed: April 16, 2018.
Alirocumab was not removed from the market and at the time of this writing is commercially available.
The author regrets the errors. All subsequent versions of the article have been corrected.